Clear All
12393 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
73043-0042-21 73043-0042 Lenalidomide Lenalidomide 20.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Jan 31, 2026 In Use
73043-0040-01 73043-0040 Lenalidomide Lenalidomide 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Jan 31, 2026 In Use
73043-0041-21 73043-0041 Lenalidomide Lenalidomide 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Jan 31, 2026 In Use
73043-0039-28 73043-0039 Lenalidomide Lenalidomide 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Jan 31, 2026 In Use
73043-0043-01 73043-0043 Lenalidomide Lenalidomide 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Jan 31, 2026 In Use
83634-0206-51 83634-0206 Cyclophosphamide Cyclophosphamide 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Feb 1, 2026 In Use
83634-0205-50 83634-0205 Cyclophosphamide Cyclophosphamide 500.0 mg/25mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Feb 1, 2026 In Use
70518-4560-00 70518-4560 PREDNISONE PREDNISONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb 2, 2026 In Use
68001-0667-01 68001-0667 Aprepitant Aprepitant 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Feb 2, 2026 In Use
85043-0075-50 85043-0075 Leuprolide acetate Vabrinty 7.5 mg/.25mL Hormonal Therapy GnRH Agonist Subcutaneous Feb 2, 2026 In Use
68001-0666-17 68001-0666 Aprepitant Aprepitant 40.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Feb 2, 2026 In Use
68001-0669-15 68001-0669 Aprepitant Aprepitant 80.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Feb 3, 2026 In Use
68071-3746-03 68071-3746 PREDNISONE PREDNISONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb 4, 2026 In Use
65145-0192-25 65145-0192 Methylprednisolone Acetate Methylprednisolone Acetate 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intralesional, Intramuscular, Soft Tissue Feb 6, 2026 In Use
65145-0193-25 65145-0193 Methylprednisolone Acetate Methylprednisolone Acetate 80.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intralesional, Intramuscular, Soft Tissue Feb 6, 2026 In Use
70518-4524-04 70518-4524 Prednisolone Sodium Phosphate Prednisolone Sodium Phosphate 15.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb 9, 2026 In Use
68001-0668-19 68001-0668 Aprepitant Aprepitant 125.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Feb 10, 2026 In Use
69097-0429-96 69097-0429 Filgrastim-txid NYPOZI 480.0 ug/480ug Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb 11, 2026 In Use
69097-0430-96 69097-0430 Filgrastim-txid NYPOZI 300.0 ug/300ug Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb 11, 2026 In Use
69097-0429-67 69097-0429 Filgrastim-txid NYPOZI 480.0 ug/480ug Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb 11, 2026 In Use
69097-0430-67 69097-0430 Filgrastim-txid NYPOZI 300.0 ug/300ug Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Feb 11, 2026 In Use
70518-4038-07 70518-4038 PREDNISONE Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb 11, 2026 In Use
85776-0202-30 85776-0202 Dronabinol DRONABINOL 5.0 mg/mL Ancillary Therapy Antiemetic CB1/CB2 Oral Feb 11, 2026 In Use
57894-0522-01 57894-0522 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) Rybrevant Faspro 3520.0 mg/22mL, 44000.0 mg/22mL Immunotherapy Monoclonal Antibody EGFR, MET Subcutaneous Feb 13, 2026 In Use
57894-0515-01 57894-0515 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) Rybrevant Faspro 2400.0 mg/15mL, 30000.0 mg/15mL Immunotherapy Monoclonal Antibody EGFR, MET Subcutaneous Feb 13, 2026 In Use

Found 12393 results — Export these results